Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Central serous chorioretinopathy: Towards an evidence-based treatment guideline

Research output: Contribution to journalReviewResearchpeer-review

  1. Optic nerve oxygenation

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Low physical activity and higher use of screen devices are associated with myopia at the age of 16-17 years in the CCC2000 Eye Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Reply: Is automated screening for DR indeed not yet ready as stated by Grauslund et al?

    Research output: Contribution to journalLetterResearchpeer-review

  3. Spectral-domain optical coherence tomography of retinal vessels in Waldenström's macroglobulinemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. An Expanded Test Panel for Assessment of Fringe Benefits From Cataract Surgery

    Research output: Contribution to journalComment/debateResearchpeer-review

  • Thomas J van Rijssen
  • Elon H C van Dijk
  • Suzanne Yzer
  • Kyoko Ohno-Matsui
  • Jan E E Keunen
  • Reinier O Schlingemann
  • Sobha Sivaprasad
  • Giuseppe Querques
  • Susan M Downes
  • Sascha Fauser
  • Carel B Hoyng
  • Felice Cardillo Piccolino
  • Jay K Chhablani
  • Timothy Y Y Lai
  • Andrew J Lotery
  • Michael Larsen
  • Frank G Holz
  • K Bailey Freund
  • Lawrence A Yannuzzi
  • Camiel J F Boon
View graph of relations

Central serous chorioretinopathy (CSC) is a common cause of central vision loss, primarily affecting men 20-60 years of age. To date, no consensus has been reached regarding the classification of CSC, and a wide variety of interventions have been proposed, reflecting the controversy associated with treating this disease. The recent publication of appropriately powered randomised controlled trials such as the PLACE trial, as well as large retrospective, non-randomised treatment studies regarding the treatment of CSC suggest the feasibility of a more evidence-based approach when considering treatment options. The aim of this review is to provide a comprehensive overview of the current rationale and evidence with respect to the variety of interventions available for treating CSC, including pharmacology, laser treatment, and photodynamic therapy. In addition, we describe the complexity of CSC, the challenges associated with treating CSC, and currently ongoing studies. Many treatment strategies such as photodynamic therapy using verteporfin, oral mineralocorticoid antagonists, and micropulse laser treatment have been reported as being effective. Currently, however, the available evidence suggests that half-dose (or half-fluence) photodynamic therapy should be the treatment of choice in chronic CSC, whereas observation may be the preferred approach in acute CSC. Nevertheless, exceptions can be considered based upon patient-specific characteristics.

Original languageEnglish
JournalProgress in Retinal and Eye Research
Pages (from-to)100770
Publication statusPublished - Nov 2019

ID: 59235089